top of page
Since inception late 2020, we have built a clinical stage portfolio of de-risked analgesics programs via our Personalized Analgesics® research technology.
Our novel network biology methodology to research connected to our proprietary pain landscape database of 100’s of diseases allows us to link research targets to disease and de-risked R&D
Eptiva Pipeline Projects
De-risked proprietary pipeline enables up to two NDAs and two clinical PoCs in three years
bottom of page